The mobile applications technology developed by cliexa™ enables patients to track their chronic disease activity by quantifying symptoms with scientifically-proven and clinically-validated scoring models along with medication data.
Unlike our competitors, our platform provides mobile interface to collect data from patients, and provides chronic care reporting and analytics features with EMR integration. According to recent NIH article (ncbi.nlm.nih.gov/pmc/articles/...) "Apps for People With Rheumatoid Arthritis to Monitor Their Disease Activity: A Review of Apps for Best Practice and Quality" (February 2017), cliexa-RA mobile application for Rheumatoid Arthritis has been featured as one of the top 19 RA apps among 936 Rheumatoid Arthritis mobile applications reviewed by the scientists.
Technology Validation: cliexa has partnered with Colorado Permenante Medical Group and Kaiser Permanente to perform a clinical study working with Kaiser Permanente Rheumatology Group’s patients since November 2016. Goal of this study is to measure patient engagement and further develop the application and evaluate patient reported outcomes which will be published in a joint case study.
cliexa-RA (Rheumatoid Arthritis) and cliexa-IBD (Inflammatory Bowel Disease) have been already piloted for 6 months with Kaiser Permanente. Cliexa aims to expand the mobile platform capabilities to other chronic diseases such as CHF, Afib, MS, and COPD.
Chronic diseases and their treatment overwhelm the healthcare ecosystem in the United States, with 117 Million sufferers and spending near $1.1 trillion annually (or 40% of US healthcare costs) according to National Medical Expenditures Panel Survey of 2012. This cost can easily be reduced by closing the feedback loop between patients and their doctors. Our solution is a great fit primarily for payors and providers to improve responsive and preventive care. Our team and advisors have years of expertise in these areas both from clinical and business perspective.
Past Execution/Traction: cliexa launched cliexa-RA for Rheumatoid Arthritis and cliexa-IBD for Crohn's Disease for both iOS and Android platforms in January 2016. By December 2016, cliexa launched cliexa-OPD for COPD exclusively for Kaiser Permanente. cliexa received its 513g clearance from FDA for disease management protocols in May 2016. Following this, cliexa was selected and developed first in its class through the Boomtown Health Accelerator program and recently been accepted to the Venture Hall Accelerator Program. cliexa executed a Business Associate Agreement and Technology Evaluation and Pilot Agreement with Kaiser Permanente on November 2016.
"Apps for People With Rheumatoid Arthritis to Monitor Their Disease Activity: A Review of Apps for Best Practice and Quality" (February 2017)
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.